<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426474</url>
  </required_header>
  <id_info>
    <org_study_id>17681</org_study_id>
    <secondary_id>J2A-MC-GZGC</secondary_id>
    <secondary_id>2020-000125-86</secondary_id>
    <nct_id>NCT04426474</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Participants With Type 2 Diabetes</brief_title>
  <official_title>A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3502970 and any side
      effects that might be associated with it. Blood tests will be done to measure how much
      LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it
      affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits
      (including three overnight stays) in the study center.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">April 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline through Follow-up (up to Day 105)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970</measure>
    <time_frame>Day 1 through Day 84: Predose up to 96 hours postdose</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve of LY3502970</measure>
    <time_frame>Day 1 through Day 84: Predose up to 96 hours postdose</time_frame>
    <description>PK: AUC of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Pharmacodynamics (PD): Change from Baseline to Week 12 in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Change from Baseline to Week 12 in Fasting Insulin</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>PD: Change from Baseline to Week 12 in Fasting Insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3502970</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes mellitus (T2DM) for at least 6 months

          -  Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to
             (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and
             exercise alone or a stable dose of metformin for at least 3 months prior to screening

          -  Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45
             kilograms per square meter (kg/m²), inclusive

          -  Have had a stable body weight for the 3 months prior to screening (less than [&lt;]5%
             body weight change)

          -  Males and females (not considered woman of childbearing potential)

        Exclusion Criteria:

          -  Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an
             episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6
             months prior to screening

          -  Have had any of the following within the past 6 months prior to screening: myocardial
             infarction, unstable angina, coronary artery bypass graft, percutaneous coronary
             intervention (diagnostic angiograms are permitted), transient ischemic attack,
             cerebrovascular accident or decompensated congestive heart failure, or currently have
             New York Health Association Class III or IV heart failure

          -  Show evidence of hepatitis B, and/or positive hepatitis B surface antigen

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Any glucose-lowering medications other than metformin within 3 months prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>305-817-2900</phone>
    </contact>
    <investigator>
      <last_name>Juan C Rondon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>856-452-9901</phone>
    </contact>
    <investigator>
      <last_name>HOWARD A HASSMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Unit</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>937-424-1050</phone>
    </contact>
    <investigator>
      <last_name>Steven Folkerth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>210-949-0807</phone>
    </contact>
    <investigator>
      <last_name>Hernan A Salazar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <phone>4921314018305</phone>
    </contact>
    <investigator>
      <last_name>Jorge Arrubla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <phone>4961312162700</phone>
    </contact>
    <investigator>
      <last_name>Leona Plum-Mörschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/7zwMq2LwDbIpQoxy04CHQ7?conditionId=3bqjr5JHpKymwsYAWWaicU</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

